Dr. Danuser Discusses Impact of RacP29S Mutation in Melanoma

Source: OncLive, December 2019

Gaudenz Danuser, PhD, chair of Bioinformatics at UT Southwestern Medical Center, discusses how the activation of RacP29S impacts the treatment of patients with melanoma. His lab has been studying the Rac molecule for around 20 years. The RacP29S mutation most commonly appears in melanoma, but it has since been discovered in a few other cancer types as well.